Skip to content
DataLookout
Menu

NCT07940140

Gut Barrier Function and Metabolic Risk in Women With Excessive Gestational Weight Gain

StatusActive, Not Recruiting
PhaseNot specified
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Serum Zonulin Level
Timeframe: At enrollment (≥37 weeks of gestation)
Serum I-FABP Level
Timeframe: At enrollment (≥37 weeks of gestation)
Serum GLP-2 Level
Timeframe: At enrollment (≥37 weeks of gestation)
Serum LBP Level
Timeframe: At enrollment (≥37 weeks of gestation)
Serum sCD14 Level
Timeframe: At enrollment (≥37 weeks of gestation)

Secondary (8)

Serum TNF-alpha Level
Serum IL-6 Level
Serum hs-CRP Level
Serum Vitamin D Receptor Level
Serum 25-Hydroxyvitamin D Level
Show 3 moreShow less
Fasting Blood Glucose Level
Fasting Serum Insulin Level
HOMA-IR Index

Arms and interventions

Excessive Gestational Weight Gain Group

Pregnant women with normal pre-pregnancy BMI (18.5-24.9 kg/m²) and gestational weight gain exceeding the 2009 IOM recommendations (n=40).

Recommended Gestational Weight Gain Group (Control Group)

Pregnant women with normal pre-pregnancy BMI (18.5-24.9 kg/m²) and gestational weight gain within the 2009 IOM recommended range (n=40).

Sites

1 site in 1 country

  • Sivas Cumhuriyet University Faculty of Medicine HospitalSivas, Sivas, Turkey (Türkiye)